NCT04896853

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

Treatment of Respiratory Complications Associated With COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus Infection Using Wharton's Jelly-Umbilical Cord Mesenchymal Stromal Cells (ProTrans®): Open Phase IB Clinical Trial

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (estimated)
• Sponsor: NextCell Pharma Ab · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To investigate the safety and tolerance of a single infusion of ProTrans® in subjects with "severe" respiratory complications associated with pneumonia caused by COVID-19, Influenza A, Metapneumovirus or RSV infection.

Detailed description

The investigators hypothesize that the systemic delivery of WJ-MSCs exerts an anti-inflammatory action and anti-apoptotic effect in the lung of COVID-19, Influenza A, Metapneumovirus or RSV patients. The nature of these cells to immunomodulate both tissue resident and bloodborne immune cells towards a more anti-inflammatory and tolerogenic profile, results in a reduction of tissue-based inflammation within the lung and triggering of repair responses. This clinically culminates in a beneficial action on patients with "severe" respiratory complications associated with pneumonia.

Conditions

• COVID-19 Acute Respiratory Distress Syndrome
• Influenza A
• Metapneumovirus Pneumonia
• Respiratory Syncytial Virus (RSV)

Interventions

Type	Name	Description
BIOLOGICAL	ProTrans®	Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells

Timeline

• Start date: 2021-05-18
• Primary completion: 2027-03-31
• Completion: 2027-05-31
• First posted: 2021-05-21
• Last updated: 2025-05-14

Locations

1 site across 1 country: Sweden